Skip to main content

Xbrane Biopharma

Xbrane Biopharma AB is a Swedish biotechnology company specializing in the development of biosimilars for complex biopharmaceuticals. The company utilizes its patented protein expression platform to develop biosimilars, including Ximluci, a ranibizumab biosimilar for treating age-related macular degeneration and ophthalmology conditions. Main revenue drivers consist of commercial product sales of biosimilars, milestone licensing payments, and research partnership funding. Xbrane Biopharma serves ophthalmologists, hospital eye clinics, biopharmaceutical distribution partners, and patients across Europe and North America. The company holds a specialized niche position in European biosimilar development for ophthalmic and oncology biopharmaceuticals. Headquartered in Solna, Sweden, Xbrane Biopharma AB is listed on Nasdaq Stockholm.

2 of the funds FundTelligence covers report a position in Xbrane Biopharma.

Legal name
Xbrane Biopharma AB
Sector
Health Care
Country
Sweden
Funds holding it
2

Funds holding Xbrane Biopharma

Loading...